Literature DB >> 3541056

Cholinergic receptors in aging and Alzheimer's disease.

P J Whitehouse, K S Au.   

Abstract

Although Alzheimer's disease (AD) is a disorder involving multiple neurotransmitter systems, the basal forebrain cholinergic system (Ch system) is severely and consistently affected in this condition. In both animals and man, the nature of age-associated alterations in the Ch system is unclear. In addition, available studies of cholinergic receptors in AD and aging are not consistent. In normal aging, the density of muscarinic cholinergic receptors (MCR) is reported to be either unchanged or decreased. In AD, increased, unchanged, or decreased densities have been reported. Recently, a subtype of MCR (M2), thought to be located presynaptically, has been reported to be reduced in neocortex and amygdala. In both AD and aging, nicotinic cholinergic receptors (NCR) have not been adequately studied. Our recent studies using [3H] acetylcholine and [3H] nicotine have demonstrated a reduction in NCR in AD. Possible explanations for some of the inconsistent findings are discussed, and directions for future studies are suggested.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3541056     DOI: 10.1016/0278-5846(86)90035-7

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  14 in total

1.  The M1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons.

Authors:  C Weiss; A R Preston; M M Oh; R D Schwarz; D Welty; J F Disterhoft
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 2.  Neuromodulation by glutamate and acetylcholine can change circuit dynamics by regulating the relative influence of afferent input and excitatory feedback.

Authors:  Lisa M Giocomo; Michael E Hasselmo
Journal:  Mol Neurobiol       Date:  2007-07-20       Impact factor: 5.590

Review 3.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

4.  Scopolamine disrupts place navigation in rats and humans: a translational validation of the Hidden Goal Task in the Morris water maze and a real maze for humans.

Authors:  Jan Laczó; Hana Markova; Veronika Lobellova; Ivana Gazova; Martina Parizkova; Jiri Cerman; Tereza Nekovarova; Karel Vales; Sylva Klovrzova; John Harrison; Manfred Windisch; Kamil Vlcek; Jan Svoboda; Jakub Hort; Ales Stuchlik
Journal:  Psychopharmacology (Berl)       Date:  2016-11-24       Impact factor: 4.530

Review 5.  Neurotransmitter replacement therapy in Alzheimer's disease.

Authors:  E Mohr; T Mendis; I N Rusk; J D Grimes
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

Review 6.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

7.  The developing cholinergic system as target for environmental toxicants, nicotine and polychlorinated biphenyls (PCBs): implications for neurotoxicological processes in mice.

Authors:  P Eriksson; E Ankarberg; H Viberg; A Fredriksson
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

8.  Effects of aging on the interaction of quinuclidinyl benzilate, N-methylscopolamine, pirenzepine, and gallamine with brain muscarinic receptors.

Authors:  W Surichamorn; O N Kim; N H Lee; W S Lai; E E el-Fakahany
Journal:  Neurochem Res       Date:  1988-12       Impact factor: 3.996

9.  Functional and neurobiological similarities of aging in monkeys and humans.

Authors:  M L Voytko
Journal:  Age (Omaha)       Date:  1997-01

10.  Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.

Authors:  T Sunderland; G Esposito; S E Molchan; R Coppola; D W Jones; J Gorey; J T Little; M Bahro; D R Weinberger
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.